| Market Capitalization (Millions $) |
49 |
| Shares
Outstanding (Millions) |
30 |
| Employees |
84 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-6 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Dyadic International Inc
Dyadic International Inc.
(DYAI) is a biotechnology company based in Jupiter, Florida, USA.
It specializes in developing and implementing advanced technology solutions for the discovery, development, and production of biologics such as vaccines, monoclonal antibodies, and biosimilars.
Dyadic's technology platform is based on its proprietary C1 gene expression technology which is capable of producing high levels of proteins and enzymes at a low cost.
The C1 platform is scalable, adaptable and has numerous applications in various industries including biopharmaceuticals, animal health, industrial enzymes, and biofuels.
Dyadic has established collaborations with several leading global biotech and pharmaceutical companies to develop and produce a wide range of biologics.
The company is also engaged in research and development to enhance its technology platform and expand its applications.
In addition to its biotechnology operations, Dyadic is also exploring opportunities in other related fields, including developing sustainable and environmentally-friendly products that are derived from its C1 technology.
Dyadic International Inc.
was founded in 1979 and went public in 2005.
The company has a team of over 90 employees and is led by CEO Mark Emalfarb.
It trades on the NASDAQ under the ticker symbol DYAI.
Company Address: 1044 North U.S. Highway One, Suite 201 Jupiter 33477 FL
Company Phone Number: 743-8333 Stock Exchange / Ticker: NASDAQ DYAI
|
0.11% 